Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1998
Business Overview: ImmuCell Corporation is engaged in the development and marketing of animal health products (e.g., First Defense, Kamar Heatmount Detector) and human health products (passive antibody therapies). The company also holds interests in joint ventures focused on lactoferrin production and water diagnostics.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1998 | Nine Months Ended Sep 30, 1998 | Balance Sheet (Sep 30, 1998) |
|---|---|---|---|
| Total Revenues | $1,116,910 | $3,308,332 | - |
| Product Sales | $981,037 | $3,109,687 | - |
| Net Loss | $(143,951) | $(4,923) | - |
| Operating Income (Loss) | $(59,935) | $56,954 | - |
| Cash and Equivalents | - | - | $1,330,568 |
| Net Working Capital | - | - | $1,908,123 |
| Total Debt (Current + Long Term) | - | - | $474,721 |
| Stockholders' Equity | - | - | $2,345,191 |
Gross Margin: 47% for the three months ended Sep 30, 1998; 53% for the nine months ended Sep 30, 1998.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 14% for the three months and 6% for the nine months compared to 1997. This was driven by a significant increase in grant income ($135,873 vs. $22,000 for the quarter) and modest growth in product sales.
- Profitability: The company reported a net loss of $143,951 for the quarter, compared to a loss of $3,369 in the prior year quarter. However, for the nine-month period, the net loss narrowed significantly to $4,923 from $55,834 in 1997.
- Debt Restructuring: In May 1998, the company refinanced all outstanding bank debt obligations into a single $480,000 mortgage loan secured by its building. This reduced the current portion of long-term debt from $230,274 to $15,491.
- Joint Venture Impairment: A non-cash charge of approximately $90,000 was recorded against the equity interest in AgriCell Company, LLC, due to lower-than-expected sales of lactoferrin caused by financial crises in South Korea and Japan.
- Cash Flow: Net cash provided by operating activities improved dramatically to $412,819 for the nine months ended Sep 30, 1998, compared to $2,817 in the prior year period.
Guidance, Outlook, and Risks
- Strategic Shift: Management is decreasing investment in human health products and increasing focus on animal health products, which have lower funding requirements. The company anticipates recording a profit in 1999.
- Product Discontinuation: Development of TravelGAM (bovine anti-E. COLI) was discontinued following negative clinical trial results in September 1998. Future human health efforts are limited to DiffGAM (anti-C. DIFFICILE), with a small effectiveness study expected to begin in early 1999.
- Liquidity: Management believes current capital resources are sufficient to meet working capital requirements for the next twelve months. Approximately $312,000 remains available under a Phase II SBIR grant.
- Year 2000 Issue: The company estimates costs to address Year 2000 compliance will not exceed $20,000, with completion expected in Q4 1998. Risks are deemed not material due to the ability to source supplies from multiple vendors.
- Joint Venture Dissolution: The joint venture Clearwater Diagnostics Company, LLC was dissolved in August 1998; the company retained the license to the Crypto-Scan water diagnostic test.
Investor Verification Checklist
- Grant Dependency: Verify the sustainability of grant income, which contributed significantly to the revenue increase ($198,645 for the nine months) and offset R&D expenses.
- Debt Covenants: Review the terms of the new $480,000 mortgage (8.62% fixed rate) and the balloon payment structure due in 2003.
- R&D Pipeline: Assess the timeline and funding requirements for the DiffGAM clinical study expected in 1999, as this is the primary remaining human health asset.
- Joint Venture Valuation: Confirm the remaining book value and potential for recovery of the investment in AgriCell following the $90,000 impairment charge.
- Product Concentration: Note that 93-94% of product sales are derived from two specific products (First Defense and Kamar Heatmount Detector).